Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to -$19.6 million.

  • Amphastar Pharmaceuticals' Cash from Investing Activities rose 4327.47% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.4 million, marking a year-over-year increase of 7636.99%. This contributed to the annual value of -$124.9 million for FY2024, which is 8075.38% up from last year.
  • Amphastar Pharmaceuticals' Cash from Investing Activities amounted to -$19.6 million in Q3 2025, which was up 4327.47% from -$625000.0 recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Cash from Investing Activities ranged from a high of $15.2 million in Q1 2024 and a low of -$508.6 million during Q2 2023
  • Moreover, its 5-year median value for Cash from Investing Activities was -$9.1 million (2022), whereas its average is -$44.5 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Cash from Investing Activities crashed by 4489956.33% in 2023 and then soared by 34059.69% in 2024.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Cash from Investing Activities stood at -$12.0 million in 2021, then surged by 98.08% to -$229000.0 in 2022, then tumbled by 44899.56% to -$103.0 million in 2023, then skyrocketed by 65.38% to -$35.7 million in 2024, then surged by 45.01% to -$19.6 million in 2025.
  • Its Cash from Investing Activities stands at -$19.6 million for Q3 2025, versus -$625000.0 for Q2 2025 and $10.5 million for Q1 2025.